News | May 01, 2024
Lilly posts Q1 2024 revenue up 26% at US$ 8.77 billion
2024 full-year revenue guidance raised by US$ 2 billion
2024 full-year revenue guidance raised by US$ 2 billion
Highly effective preservation solutions ensuring the safety and protection of personal care products
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
PFA technology is only marketed in Europe, and yet, it has been dominating the electrophysiology market by storm
Meningitis still affects more than 2.5 million people globally each year
Brian Foard will lead the Specialty Care GBU ad interim, effective immediately.
Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion
With close to 30-40 basic screening tests available, the unit encompasses all the essential parameters typically covered in annual health check-ups
Subscribe To Our Newsletter & Stay Updated
